CLASS ACTION UPDATE for NIO, ARA and AAPL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Thursday, April 18, 2019 1:10 PM
NEW YORK, NY / ACCESSWIRE / April 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
NIO Inc. (NYSE: NIO)
Class Period: Purchasers of American Depositary Shares between September 12, 2018 and March 5, 2019
Lead Plaintiff Deadline : May 13, 2019
Join the action: https://www.zlk.com/pslra-1/nio-inc-loss-form?prid=1174&wire=1
The lawsuit alleges: NIO Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on JAC Auto to manufacture its vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO's sales; and (3) as a result, Defendants' statements about NIO's business, operations, and prospects were materially false and misleading at all relevant times.
To learn more about the NIO Inc. class action contact [email protected].
American Renal Associates Holdings, Inc. (NYSE: ARA)
Class Period: August 10, 2016 - March 27, 2019
Lead Plaintiff Deadline : May 28, 2019
Join the action: https://www.zlk.com/pslra-1/american-renal-associates-holdings-inc-loss-form?prid=1174&wire=1
The lawsuit alleges that, during the class period, American Renal Associates Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (''SEC'') investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.
To learn more about the American Renal Associates Holdings, Inc. class action contact [email protected].
Apple Inc. (NASDAQGS: AAPL)
Class Period: November 2, 2018 - January 2, 2019
Lead Plaintiff Deadline : June 17, 2019
Join the action: https://www.zlk.com/pslra-1/apple-inc-loss-form?prid=1174&wire=1
The lawsuit alleges: Apple Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (a) the U.S.-China trade war had negatively impacted demand for iPhones and Apple's pricing power in greater China, one of Apple's most important growth markets; (b) the rate at which Apple customers were replacing their batteries in older iPhones rather than purchasing new iPhones was negatively impacting Apple's iPhone sales growth; (c) as a result of slowing demand, Apple had slashed production orders from suppliers for the new 2018 iPhone models and cut prices to reduce inventory; (d) unit sales for iPhone and other hardware was relevant to investors and the Company's financial performance, and the decision to withhold such unit sales was designed to and would mask declines in unit sales of the Company's flagship product; and (e) as a result of the foregoing, defendants lacked a reasonable basis in fact when issuing the Company's revenue outlook for the first quarter 2019 and/or making the related statements concerning demand for its products, as Apple's business metrics and financial prospects were not as strong as defendants had led the market to believe.
To learn more about the Apple Inc. class action contact [email protected].
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP